Moderna said on Tuesday that the company has begun to use the vaccine in children from 6 months old to under 12 years in the mid-to late-stage study of its coronavirus vaccine mRNA-1273.
According to Reuters, the study will evaluate the safety and effectiveness of two doses of mRNA-1273 vaccine 28 days apart and plans to recruit approximately 6,750 children in the United States and Canada. The vaccine has been authorized for emergency use by Americans 18 years and older.
In another study that started in December last year, Moderna is testing mRNA-1273 in adolescents between 12 and 18 years old. The latest research was conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Administration (BARDA).